IRWD vs. LGND, MNKD, DVAX, INVA, ZNTL, OPK, CYRX, GERN, IGMS, and LXRX
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Ligand Pharmaceuticals (LGND), MannKind (MNKD), Dynavax Technologies (DVAX), Innoviva (INVA), Zentalis Pharmaceuticals (ZNTL), OPKO Health (OPK), Cryoport (CYRX), Geron (GERN), IGM Biosciences (IGMS), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "pharmaceutical preparations" industry.
Ligand Pharmaceuticals (NASDAQ:LGND) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Ligand Pharmaceuticals' net margin of -226.37%. Ironwood Pharmaceuticals' return on equity of 11.98% beat Ligand Pharmaceuticals' return on equity.
Ligand Pharmaceuticals received 27 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 69.92% of users gave Ligand Pharmaceuticals an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Ligand Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ligand Pharmaceuticals and Ligand Pharmaceuticals both had 4 articles in the media. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat Ligand Pharmaceuticals' score of 0.57 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ligand Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Ligand Pharmaceuticals currently has a consensus target price of $116.33, indicating a potential upside of 64.85%. Ironwood Pharmaceuticals has a consensus target price of $19.80, indicating a potential upside of 153.20%. Given Ligand Pharmaceuticals' higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Ligand Pharmaceuticals.
Summary
Ligand Pharmaceuticals beats Ironwood Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
